title: Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
abstract: OBJECTIVE
  Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Chemotherapy-naïve patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m(2)) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m(2)) plus carboplatin (same dose), on day 1 every 21 days. The primary end-point was progression-free survival (PFS).
  
  
  RESULTS
  A total of 90 patients were enrolled. Overall response rate, median PFS and median survival time in the docetaxel-plus-carboplatin group and the paclitaxel-plus-carboplatin group were 23% vs. 33%, 4.8 months vs. 5.1 months, and 17.6 months vs. 15.6 months, respectively. The docetaxel-plus-carboplatin group had a higher incidence of grade 3 or 4 neutropenia (88% vs. 60%).
  
  
  CONCLUSIONS
  Both regimens were similarly effective in Japanese patients with advanced NSCLC.
authors.affiliation: 1-5-34, Otemae, Chuo-ku, Osaka, 540-0008, Japan. kawaharam@otemae.gr.jp.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawahara
authors.forename: Shinji
authors.initials: S
authors.lastname: Atagi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Komuta
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Yoshioka
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kawasaki
authors.forename: Yuka
authors.initials: Y
authors.lastname: Fujita
authors.forename: Toshiro
authors.initials: T
authors.lastname: Yonei
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Ogushi
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kubota
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Nogami
authors.forename: Michiko
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Shibata
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Tomizawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Minato
authors.forename: Kazuya
authors.initials: K
authors.lastname: Fukuoka
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Asami
authors.forename: Takeharu
authors.initials: T
authors.lastname: Yamanaka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel
keywords: Non-small cell lung cancer; chemotherapy; docetaxel; ethnicity; paclitaxel carboplatin; randomized phase 2